POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo attack on stomach cancer shows early promise
Disease control Recruiting nowThis early-phase trial tests two drugs, pembrolizumab and lenvatinib, in about 15 people with advanced stomach or gastroesophageal cancer that has spread or can't be surgically removed. Pembrolizumab helps the immune system fight cancer, while lenvatinib blocks enzymes that help …
Matched conditions: POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 10:11 UTC
-
New drug combo hopes to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a combination of two drugs—trifluridine/tipiracil (a chemotherapy) and talazoparib (a targeted therapy)—in people with advanced colorectal or gastroesophageal cancers that have spread. The main goals are to find the safest dose and understand side eff…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 22, 2026 14:03 UTC